Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer.
Kothari R, Doshi M, Chaithanya PK, Ct S, Kumar A, Mallavarapu KM, Nagarkar R, Mahobia V, Bhatt N, Priyadarshini KL, Gogia A, Maksud T, Prasad S, Velavan K, L K R, Ss P, Talreja V, Kalra K, Nemade B, Dastidar AG, Gupta T, Patil T, Bondarde S, Patel P, Gupta S, Biswas G, Vaghela M, Mahato P, Parekh H, Kalloli M, Shetty R, Prakash G, Goel A, Mandal S, Choudhury T, Jain M, Goswami C, H M YK, Mukherjee KK, Shrivastava R, Parmar D. Kothari R, et al. Among authors: parmar d. Clin Breast Cancer. 2024 Oct;24(7):639-646.e2. doi: 10.1016/j.clbc.2024.07.001. Epub 2024 Jul 10. Clin Breast Cancer. 2024. PMID: 39069436 Clinical Trial.
Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India.
Chiradoni Thungappa S, Maksud T, Raut N, Nagarkar R, Batra U, Kumar S, Parmar D; Study Investigator Group. Chiradoni Thungappa S, et al. Among authors: parmar d. Clin Breast Cancer. 2022 Jun;22(4):300-307. doi: 10.1016/j.clbc.2021.11.006. Epub 2021 Nov 27. Clin Breast Cancer. 2022. PMID: 34955432 Clinical Trial.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants.
Kansagra KA, Momin T, Patel HB, Shah C, Parmar G, Ghoghari A, Patel HV, Parmar DV. Kansagra KA, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Jul;397(7):4737-4745. doi: 10.1007/s00210-023-02912-9. Epub 2023 Dec 23. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38141084 Clinical Trial.
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Krishnappa M, Patil K, Parmar K, Trivedi P, Mody N, Shah C, Faldu K, Maroo S; PRESS XII study group; Parmar D. Krishnappa M, et al. Among authors: parmar d, parmar k. Cardiovasc Diabetol. 2020 Jun 19;19(1):93. doi: 10.1186/s12933-020-01073-w. Cardiovasc Diabetol. 2020. PMID: 32560724 Free PMC article. Clinical Trial.
Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND).
Agrawal D, Varade D, Shah H, Nazar A, Krishnan J, Shukla V, Ramakrishna C, Bandara Galahitiyawa MC, Mavani SB, Rajanna S, Jikki P, De Silva S, Ruhela V, Koradia P, Kansagra K, Kanani P, Sharma N, Zala K, Parmar D; Study Investigator Group. Agrawal D, et al. Among authors: parmar d. Am J Nephrol. 2022;53(5):352-360. doi: 10.1159/000523961. Epub 2022 Apr 22. Am J Nephrol. 2022. PMID: 35462372 Free article. Clinical Trial.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose).
Parmar DV, Kansagra KA, Momin T, Patel HB, Jansari GA, Bhavsar J, Shah C, Patel JM, Ghoghari A, Barot A, Sharma B, Viswanathan K, Patel HV, Jain MR. Parmar DV, et al. Clin Pharmacol Drug Dev. 2023 Feb;12(2):202-211. doi: 10.1002/cpdd.1162. Epub 2022 Sep 5. Clin Pharmacol Drug Dev. 2023. PMID: 36065092 Free PMC article. Clinical Trial.
A Food-Effect Study to Evaluate the Oral Bioavailability of Desidustat.
Patel H, Momin T, Kansagra K, Patel H, Shah C, Barot A, Bhavsar J, Zala K, Parmar D. Patel H, et al. Among authors: parmar d. Clin Pharmacol Drug Dev. 2023 Apr;12(4):356-362. doi: 10.1002/cpdd.1206. Epub 2022 Dec 2. Clin Pharmacol Drug Dev. 2023. PMID: 36458679 Clinical Trial.
Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India.
Momin T, Kansagra K, Patel H, Sharma S, Sharma B, Patel J, Mittal R, Sanmukhani J, Maithal K, Dey A, Chandra H, Rajanathan CT, Pericherla HP, Kumar P, Narkhede A, Parmar D. Momin T, et al. Among authors: parmar d. EClinicalMedicine. 2021 Aug;38:101020. doi: 10.1016/j.eclinm.2021.101020. Epub 2021 Jul 17. EClinicalMedicine. 2021. PMID: 34308319 Free PMC article.
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.
Barber BE, Fernandez M, Patel HB, Barcelo C, Woolley SD, Patel H, Llewellyn S, Abd-Rahman AN, Sharma S, Jain M, Ghoghari A, Di Resta I, Fuchs A, Deni I, Yeo T, Mok S, Fidock DA, Chalon S, Möhrle JJ, Parmar D, McCarthy JS, Kansagra K. Barber BE, et al. Among authors: parmar d. Lancet Infect Dis. 2022 Jun;22(6):879-890. doi: 10.1016/S1473-3099(21)00679-4. Epub 2022 Mar 2. Lancet Infect Dis. 2022. PMID: 35247321 Clinical Trial.
517 results